Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics completed two major financings, issuing $250,000,000 of 1.75% Convertible Senior Notes due 2032 and closing a public equity offering of 7,352,942 common shares at $17.00 per share.
The notes pay 1.75% interest semiannually and are convertible at an initial rate of 40.5680 shares per $1,000 principal amount, implying a conversion price of about $24.65 per share, with potential increases upon certain “Make-Whole Fundamental Change” events. Net proceeds from the convertible notes were approximately $242.0 million.
The equity offering generated net proceeds of about $117.0 million. Viridian plans to use combined proceeds to repay all outstanding debt under its Hercules Capital loan, fund market expansion studies for its thyroid eye disease franchise, advance earlier-stage R&D, and for working capital and other general corporate purposes.
Viridian Therapeutics received a Schedule 13G disclosure reporting a 5,417,660-share position (5.30% of the class) held by Deep Track entities and David Kroin. The filing states the position reflects 102,206,571 shares outstanding as of February 20, 2026. The reporting persons indicate shared voting and dispositive power over the 5,417,660 shares; sole voting and dispositive power are reported as 0. The filing is a joint Schedule 13G by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and includes a parent/subsidiary attribution note naming Deep Track Capital, LP as the relevant entity.
Viridian Therapeutics is offering $225.0 million aggregate principal amount of 1.75% convertible senior notes due May 15, 2032, with an underwriter option for an additional $25.0 million. The notes carry an initial conversion rate of 40.5680 shares per $1,000 (initial conversion price ~$24.65 per share), pay interest semi-annually at 1.75%, and may be settled in cash, shares or a combination at the company’s election. The offering is concurrent with a separate public equity offering (aggregate of $125.0 million, or up to $143.75 million if the option is exercised) and Viridian expects to use proceeds, together with the concurrent equity proceeds, to repay the Hercules Loan and fund R&D, market expansion studies and general corporate purposes. The supplement also discloses positive topline REVEAL-2 phase 3 results for elegrobart and an anticipated BLA submission in Q1 2027.
Viridian Therapeutics is offering 7,352,942 shares of common stock at a public offering price of $17.00 per share, expected to raise approximately $117.0 million in net proceeds before expenses (assuming no exercise of the underwriters' option).
Concurrently, Viridian is conducting a separate Concurrent Convertible Notes Offering of 1.75% convertible senior notes due 2032 with an aggregate principal amount of $225.0 million (or $250.0 million if the underwriters’ option is exercised). The company intends to use proceeds to repay the Hercules loan, fund market expansion studies for its TED franchise and advance R&D, and for working capital and general corporate purposes.
Viridian Therapeutics is offering $150.0 million aggregate principal amount of % convertible senior notes due 2032. The notes pay semi‑annual interest, mature on May 15, 2032, and include an underwriter option to purchase up to an additional $22.5 million. Conversions may be settled in cash, shares or a combination and are permitted only upon specified triggers until February 15, 2032, after which conversions are permitted at holder election. The offering is concurrent with a planned $100.0 million equity offering and the company expects to use proceeds to repay its Hercules secured loan, fund market expansion studies for its TED franchise, advance earlier‑stage R&D, and for working capital. Separately, Viridian announced positive topline REVEAL‑2 Phase 3 results for elegrobart (N=204), meeting primary and key secondary endpoints, and plans a BLA submission in Q1 2027.
Viridian Therapeutics is offering $150.0 million aggregate principal amount of % convertible senior notes due 2032. The notes pay semi‑annual interest, mature on May 15, 2032, and include an underwriter option to purchase up to an additional $22.5 million. Conversions may be settled in cash, shares or a combination and are permitted only upon specified triggers until February 15, 2032, after which conversions are permitted at holder election. The offering is concurrent with a planned $100.0 million equity offering and the company expects to use proceeds to repay its Hercules secured loan, fund market expansion studies for its TED franchise, advance earlier‑stage R&D, and for working capital. Separately, Viridian announced positive topline REVEAL‑2 Phase 3 results for elegrobart (N=204), meeting primary and key secondary endpoints, and plans a BLA submission in Q1 2027.
Viridian Therapeutics is offering $150.0 million aggregate principal amount of % convertible senior notes due 2032. The notes pay semi‑annual interest, mature on May 15, 2032, and include an underwriter option to purchase up to an additional $22.5 million. Conversions may be settled in cash, shares or a combination and are permitted only upon specified triggers until February 15, 2032, after which conversions are permitted at holder election. The offering is concurrent with a planned $100.0 million equity offering and the company expects to use proceeds to repay its Hercules secured loan, fund market expansion studies for its TED franchise, advance earlier‑stage R&D, and for working capital. Separately, Viridian announced positive topline REVEAL‑2 Phase 3 results for elegrobart (N=204), meeting primary and key secondary endpoints, and plans a BLA submission in Q1 2027.
Viridian Therapeutics is offering an aggregate of $100,000,000 of common stock and Series B non‑voting convertible preferred stock. Each Series B share converts into 66.67 shares of common stock, subject to a Series B Beneficial Ownership Limitation. The company is conducting a concurrent offering of convertible senior notes in an aggregate principal amount of $150,000,000 (with an over-allotment option) that is not contingent on this equity offering. Recent clinical news: topline REVEAL-2 phase 3 results for elegrobart met primary and key secondary endpoints with strong statistical significance (p<0.0001) and the company plans to submit a BLA in Q1 2027. The company’s common stock trades on Nasdaq at $14.06 per share (last reported on May 4, 2026).
Viridian Therapeutics is offering an aggregate of $100,000,000 of common stock and Series B non‑voting convertible preferred stock. Each Series B share converts into 66.67 shares of common stock, subject to a Series B Beneficial Ownership Limitation. The company is conducting a concurrent offering of convertible senior notes in an aggregate principal amount of $150,000,000 (with an over-allotment option) that is not contingent on this equity offering. Recent clinical news: topline REVEAL-2 phase 3 results for elegrobart met primary and key secondary endpoints with strong statistical significance (p<0.0001) and the company plans to submit a BLA in Q1 2027. The company’s common stock trades on Nasdaq at $14.06 per share (last reported on May 4, 2026).
Viridian Therapeutics is offering an aggregate of $100,000,000 of common stock and Series B non‑voting convertible preferred stock. Each Series B share converts into 66.67 shares of common stock, subject to a Series B Beneficial Ownership Limitation. The company is conducting a concurrent offering of convertible senior notes in an aggregate principal amount of $150,000,000 (with an over-allotment option) that is not contingent on this equity offering. Recent clinical news: topline REVEAL-2 phase 3 results for elegrobart met primary and key secondary endpoints with strong statistical significance (p<0.0001) and the company plans to submit a BLA in Q1 2027. The company’s common stock trades on Nasdaq at $14.06 per share (last reported on May 4, 2026).
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.